ABBV · News · 20261001N
Acquisition / Partnership / Divestiture
AbbVie Inc. · 2026-10-01 · Importance 34 · Surprise 42 · In source text
AbbVie participated in a concurrent private placement for ADARx Pharmaceuticals alongside ADARx’s initial public offering. ADARx raised approximately $513.2 million in gross IPO proceeds after selling 30,187,500 shares, including 3,937,500 shares from the underwriters’ full exercise option, at $17.00 per share. The IPO and AbbVie private placement together generated approximately $602.5 million in aggregate gross proceeds, implying roughly $89.3 million from the AbbVie-financed placement. ADARx is developing next-generation siRNA therapeutics for multiple diseases, providing AbbVie with exposure to a late-stage biotechnology pipeline.
Key facts
- Including a concurrent private placement with AbbVie, the aggregate gross proceeds from ADARx Pharmaceuticals' IPO and the concurrent private placement reached approximately $602.5 million. source
- AbbVie's stock climbs 25.4% in six months. source
- AbbVie has a reported payout ratio of 85%. source
- Zacks reported AbbVie's stock has seen a -0.1% return over the past month and that the company holds a Zacks Rank #3 (Hold). source
- AbbVie announced it will host a conference call to discuss its third-quarter 2026 earnings. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | — | Including a concurrent private placement with AbbVie, the aggregate gross proceeds from ADARx Pharmaceuticals' IPO and the concurrent… |
| assets | positive | committed | — | Including a concurrent private placement with AbbVie, the aggregate gross proceeds from ADARx Pharmaceuticals' IPO and the concurrent… |